Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 5/20 | 1.00 |
| ▸ | FLT1 | P17948 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 1/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 1/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 1/20 | 1.00 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CASK | O14936 | 2/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 5/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17816392 | 0.92 | TGFBR1 (0.85) | TGFBR1FLT1FLT4KDRMAPK8 | |
| SCHEMBL12426258 | 0.80 | TGFBR1 (0.66) | TGFBR1FLT1FLT4KDRMAPK8 | |
| SCHEMBL13649369 | 0.78 | TGFBR1 (0.64) | TGFBR1FLT1FLT4KDRMAPK8 | |
| SCHEMBL2127316 | 0.78 | TGFBR1 (0.63) | TGFBR1FLT1FLT4KDRMAPK8 | |
| SCHEMBL2126113 | 0.76 | TGFBR1 (0.60) | TGFBR1FLT1FLT4KDRMAPK8 | |
| SCHEMBL2128877 | 0.71 | TGFBR1 (0.54) | TGFBR1FLT1FLT4KDRMAPK8 | |
| SCHEMBL18414724 | 0.71 | TGFBR1 (1.00) | TGFBR1TGFBR2 | |
| SCHEMBL2128085 | 0.69 | TGFBR1 (0.77) | TGFBR1FLT1FLT4KDRMAPK8 | |
| SCHEMBL17816391 | 0.69 | TGFBR1 (0.51) | TGFBR1FLT1FLT4KDRMAPK8 | |
| SCHEMBL2212684 | 0.69 | TGFBR1 (0.64) | TGFBR1FLT1FLT4KDRMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951075-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-24 | — | — | US | disclosed |
| US-9951075-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-24 | — | — | US | disclosed |
| US-20170275288-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275288-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275288-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-28 | — | — | US | disclosed |
| US-9708328-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2017-07-18 | — | — | US | disclosed |
| US-9708328-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2017-07-18 | — | — | US | disclosed |
| US-9708328-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2017-07-18 | — | — | US | disclosed |
| US-20160159803-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | Janssen Sciences Ireland Unlimited Company (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20160158238-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | Janssen Sciencies Ireland UC (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20160159803-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | Janssen Sciences Ireland Unlimited Company (IE) | 2016-06-09 | — | — | US | disclosed |
| US-9290502-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-22 | — | — | US | disclosed |
| US-9290502-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-22 | — | — | US | disclosed |
| US-9290502-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-22 | — | — | US | disclosed |
| EP-1881834-B1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | JANSSEN R & D IRELAND (IE) | 2012-04-25 | — | — | EP | disclosed |
| US-20090156595-A1 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156595-A1 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156595-A1 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-06-18 | — | — | US | disclosed |
| EP-1881834-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006120251-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159803-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | HCCS, HAVCR2, MAVS | TGFBR1 4569/4885FLT1 3309/4885FLT4 3229/4885 |
| US-20170275288-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | HCCS, HAVCR2, MAVS | TGFBR1 4569/4885FLT1 3309/4885FLT4 3229/4885 |
| US-20160158238-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | HCCS, HAVCR2, MAVS | TGFBR1 4569/4885FLT1 3309/4885FLT4 3229/4885 |
| US-20090156595-A1 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | HCCS, HAVCR2, MAVS | TGFBR1 4569/4885FLT1 3309/4885FLT4 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.